RUNX1 and cancer: As shown in Fig. 7A, one or more alterations were detected in 33 types of human cancers, and 9.5% (19 cases) of patients with AML (200 cases) were observed to have mutations in RUNX1, representing the highest frequency among all patients with cancer.